Sanofi (SNY) said Thursday it has completed its acquisition of Vicebio, adding an early-stage respiratory virus vaccine program and related design technology.

The deal brings in a combination vaccine candidate targeting respiratory syncytial virus and human metapneumovirus, along with Vicebio's Molecular Clamp platform, the company said.

The program is expected to broaden Sanofi's respiratory vaccine portfolio and will also add a non-mRNA option to Sanofi's pipeline for RSV and HMPV virus treatment, it said.